We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
24 hedge funds and large institutions have $2.65M invested in CASI Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
4% more funds holding
Funds holding: 23 → 24 (+1)
2.22% less ownership
Funds ownership: 20.48% → 18.26% (-2.2%)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
55% less capital invested
Capital invested by funds: $5.93M → $2.65M (-$3.28M)
Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$66.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$22K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$21.3K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.34K |
| 5 |
Renaissance Technologies
New York
|
+$550 |
Top Sellers
| 1 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
-$994K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.1K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$6.05K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.91K |
| 5 |
Morgan Stanley
New York
|
-$2.06K |
